João Pedro Ferreira1, Mário Santos2, Sofia Almeida3, Irene Marques2, Paulo Bettencourt4, Henrique Carvalho2. 1. Centro Hospitalar do Porto, Portugal. Electronic address: jp7ferreira@hotmail.com. 2. Centro Hospitalar do Porto, Portugal. 3. Climate Change Impacts, Adaptation and Mitigation Research Group (CC-IAM), Faculdade de Ciências, Universidade de Lisboa, Portugal. 4. Centro Hospitalar de São João, Portugal.
Abstract
BACKGROUND/ OBJECTIVES:Mineralocorticoid receptor antagonist (MRA) use in acutely decompensated chronic heart failure (ADCHF) may improve congestion through diuretic effect and prevent neurohormonal activation. We aimed to evaluate the clinical effect and safety of spironolactone in ADCHF. METHODS: Prospective, experimental, single-center, and single-blinded trial. Patients were treated with: standard ADCHF therapy or oral spironolactone 50-100mg/d plus standard ADCHF therapy. RESULTS: During a 1year period, 100 patients were enrolled, 50 included in the treatment group. Mean (SD) spironolactone dose (mg) at day 1 was 94.5±23.3 and at day 3 was 62.7±24.3. Worsening renal function (increase in pCr≥0.3mg/dL from day 1 to day 3) was more likely to occur in control group (20% vs. 4%; p=0.038), serum potassium did not differ between groups, and plasma NTproBNP had a significant decrease in spironolactone group at day 3 (median [IQR], 2488 [4579] vs. 1555 [1832]; p=0.05). Furthermore, a greater proportion of patients in the treatment group were free of congestion at day 3: less edema, rales, jugular venous pressure (JVP) and orthopnea (all, p<0.05). In addition, a significantly higher proportion of patients were on oral furosemide at day 3 (44% vs. 82%; p<0.001). CONCLUSIONS: Our study supports the safety of high dose spironolactone in ADCHF and suggests a positive impact in the resolution of congestion. The important findings of our pilot study need to be confirmed in larger trials.
RCT Entities:
BACKGROUND/ OBJECTIVES:Mineralocorticoid receptor antagonist (MRA) use in acutely decompensated chronic heart failure (ADCHF) may improve congestion through diuretic effect and prevent neurohormonal activation. We aimed to evaluate the clinical effect and safety of spironolactone in ADCHF. METHODS: Prospective, experimental, single-center, and single-blinded trial. Patients were treated with: standard ADCHF therapy or oral spironolactone 50-100mg/d plus standard ADCHF therapy. RESULTS: During a 1year period, 100 patients were enrolled, 50 included in the treatment group. Mean (SD) spironolactone dose (mg) at day 1 was 94.5±23.3 and at day 3 was 62.7±24.3. Worsening renal function (increase in pCr≥0.3mg/dL from day 1 to day 3) was more likely to occur in control group (20% vs. 4%; p=0.038), serum potassium did not differ between groups, and plasma NTproBNP had a significant decrease in spironolactone group at day 3 (median [IQR], 2488 [4579] vs. 1555 [1832]; p=0.05). Furthermore, a greater proportion of patients in the treatment group were free of congestion at day 3: less edema, rales, jugular venous pressure (JVP) and orthopnea (all, p<0.05). In addition, a significantly higher proportion of patients were on oral furosemide at day 3 (44% vs. 82%; p<0.001). CONCLUSIONS: Our study supports the safety of high dose spironolactone in ADCHF and suggests a positive impact in the resolution of congestion. The important findings of our pilot study need to be confirmed in larger trials.
Authors: Stephen J Greene; G Michael Felker; Anna Giczewska; Andreas P Kalogeropoulos; Andrew P Ambrosy; Hrishikesh Chakraborty; Adam D DeVore; Marat Fudim; Steven E McNulty; Robert J Mentz; Muthiah Vaduganathan; Adrian F Hernandez; Javed Butler Journal: Can J Cardiol Date: 2019-02-07 Impact factor: 5.223
Authors: Javed Butler; Kevin J Anstrom; G Michael Felker; Michael M Givertz; Andreas P Kalogeropoulos; Marvin A Konstam; Douglas L Mann; Kenneth B Margulies; Steven E McNulty; Robert J Mentz; Margaret M Redfield; W H Wilson Tang; David J Whellan; Monica Shah; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald Journal: JAMA Cardiol Date: 2017-09-01 Impact factor: 14.676
Authors: João Pedro Ferreira; Nicolas Girerd; Pedro Bettencourt Medeiros; Miguel Bento Ricardo; Tiago Almeida; Alexandre Rola; Faiez Zannad; Patrick Rossignol; Irene Aragão Journal: Cardiorenal Med Date: 2017-01-21 Impact factor: 2.041
Authors: Jozine M ter Maaten; Mattia A E Valente; Kevin Damman; Hans L Hillege; Gerjan Navis; Adriaan A Voors Journal: Nat Rev Cardiol Date: 2015-01-06 Impact factor: 32.419
Authors: Javed Butler; Adrian F Hernandez; Kevin J Anstrom; Andreas Kalogeropoulos; Margaret M Redfield; Marvin A Konstam; W H Wilson Tang; G Michael Felker; Monica R Shah; Eugene Braunwald Journal: JACC Heart Fail Date: 2016-08-10 Impact factor: 12.035
Authors: João Pedro Ferreira; Nicolas Girerd; Pedro Bettencourt Medeiros; Mário Santos; Henrique Cyrne Carvalho; Paulo Bettencourt; David Kénizou; Javed Butler; Faiez Zannad; Patrick Rossignol Journal: Clin Res Cardiol Date: 2015-11-28 Impact factor: 5.460